Mushrooms & Drug Interactions
77 Clinical Trials
A 2020 systematic review found that mushroom supplements combined with cytotoxic chemotherapy improved immune outcomes across 77 clinical trials, with no adverse interactions documented. Organ transplant patients face a different and unstudied situation.
Lam et al., Chinese Medicine, 2020
0 adverse interactions
across 77 clinical trials of mushroom and chemotherapy combinations
No transplant data
no clinical studies have tested mushrooms with cyclosporine or tacrolimus
CYP3A4 concern
reishi triterpenoids inhibit the enzyme that metabolizes cyclosporine
Lam et al., Chinese Medicine, 2020
View as image ↗For people taking immunosuppressants, mushroom supplement safety is not a simple question. The answer depends almost entirely on why you are taking the immunosuppressant in the first place.
Medicinal mushrooms are documented immune activators. Turkey tail's PSK stimulates natural killer cells. Reishi beta-glucans modulate macrophage activity. Chaga activates innate immune responses. For most people, this immune-activating activity is exactly why they take these supplements. For people already on immunosuppressants, it creates a pharmacological tension that requires different answers for different patient groups.
A 2020 systematic review by Lam and colleagues[1] analyzed 213 studies of mushroom supplements combined with cytotoxic chemotherapy, including 77 clinical trials in human patients. Across all 77 clinical studies, the findings were consistent: no adverse interactions, and generally improved immune outcomes. That is a substantial body of evidence. But the patients in those studies were cancer patients, whose immunosuppression was an unwanted side effect of treatment. Organ transplant recipients, who take immunosuppressants permanently and deliberately to prevent organ rejection, represent a pharmacologically different situation with no equivalent clinical evidence base.
Understanding both cases is the subject of this article. For a broader look at how medicinal mushrooms interact across multiple drug classes, see Medicinal Mushrooms and Drug Interactions: A Complete Guide. For the underlying pharmacology of how extraction methods determine which active compounds reach the bloodstream, see Mushroom Extraction Methods Explained.
Key Takeaways
- Lam et al.'s 2020 systematic review analyzed 77 clinical trials of mushroom supplements combined with chemotherapy and found no adverse interactions, with improved immune cell counts and survival outcomes in favor of the mushroom groups
- This evidence applies to cancer patients experiencing chemotherapy-induced immunosuppression, where restoring immune activity aligns with the treatment goal
- Organ transplant recipients take cyclosporine and tacrolimus specifically to prevent their immune system from attacking donor tissue; no clinical studies exist for this population combined with mushroom supplements
- Turkey tail (PSK and PSP) carries the strongest immunomodulatory evidence of any medicinal mushroom and is the highest-concern species for transplant patients on immune-stimulation grounds
- Reishi raises a second concern beyond immune stimulation: its triterpenoids inhibit CYP3A4, the liver enzyme that metabolizes cyclosporine, which could theoretically raise drug blood levels and cause toxicity
- The honest summary: for cancer patients on chemotherapy, the evidence is reassuring; for transplant patients, the evidence simply does not exist
The Two Types of Immunosuppression: Why One Has Clinical Evidence, One Doesn't
The key to understanding this question is recognizing that not all immunosuppression serves the same purpose.
Cancer chemotherapy suppresses the immune system as an unintended side effect. The drugs target rapidly dividing cells, which includes cancer cells but also includes immune cells. Patients undergoing chemotherapy experience reduced immune function as collateral damage, and oncologists actively work to minimize this. Adding mushroom supplements that help restore immune activity works with the treatment goal in this context. The immunosuppression is the adversary; anything that reduces it helps.
Organ transplant immunosuppression is intentional and irreplaceable. Drugs like cyclosporine, tacrolimus, mycophenolate, and prednisone suppress the immune system on purpose. They prevent the body from recognizing donor tissue as foreign and mounting an attack against it. Without precise immunosuppression, transplanted organs fail. The therapeutic window is extremely narrow: too little suppression leads to rejection; too much suppression leaves the patient vulnerable to serious infections. Adding any agent that stimulates immune activity runs directly counter to the treatment goal.
These two situations are pharmacologically opposite. Evidence built in one context does not transfer to the other, even when the drugs in both contexts are called "immunosuppressants."
How Mushrooms Activate Immune Cells, and Why That's the Concern
The primary immunomodulatory compounds in medicinal mushrooms are beta-glucans, long-chain polysaccharides that bind to specific docking sites on immune cells.
When beta-glucans attach to these receptors on macrophages (the immune system's frontline cleanup cells), natural killer cells (the rapid-response team that targets infected or abnormal cells), and T-lymphocytes (the adaptive immune soldiers that coordinate targeted attacks), they trigger these cells to activate and release signaling proteins that put the broader immune system on alert. This is not a diffuse, nonspecific boost. It is a targeted activation of the innate immune system, specifically the surveillance and rapid-response pathways.
Turkey tail (Trametes versicolor) contains PSK, known as polysaccharide-K, and PSP, polysaccharide-peptide. These are the best-characterized immunomodulatory compounds in any medicinal mushroom. PSK has been approved in Japan as an adjunctive cancer treatment specifically to restore immune cell counts that chemotherapy depletes. Reishi (Ganoderma lucidum) contains both beta-glucans and triterpenoids. The beta-glucans contribute to immune activation; the triterpenoids have additional effects on drug-metabolizing liver enzymes, covered separately below. Chaga (Inonotus obliquus) carries a high beta-glucan content and activates innate immunity, though with a thinner clinical evidence base than turkey tail.
For a transplant patient, the mechanism is the concern. Cyclosporine and tacrolimus work by blocking a specific signaling pathway inside T-lymphocytes, preventing them from multiplying and attacking donor tissue. Beta-glucans from turkey tail, reishi, or chaga activate those same T-lymphocytes. The two interventions work in opposing directions at the cellular level.
What 77 Clinical Trials Found for Cancer Patients
The most comprehensive evidence on mushrooms and immunosuppressive therapy comes from a 2020 systematic review by Lam and colleagues, published in the journal Chinese Medicine.[1]
Lam et al. reviewed 213 studies of Lingzhi (reishi) and Yunzhi (turkey tail) combined with cytotoxic chemotherapy drugs. Of those 213 studies, 77 were clinical trials in human patients. Across those clinical studies, the findings were consistent:
- Patients receiving mushroom supplements alongside chemotherapy showed improved immune cell counts compared to chemotherapy alone
- Survival outcomes improved in several cancer types
- Quality-of-life ratings were generally higher in the mushroom groups
- Chemotherapy-induced immunosuppression was less severe when mushrooms were included
The review documented no adverse interactions between mushrooms and cytotoxic drugs. Two pharmacokinetic studies within the review specifically examined whether PSK altered the metabolism of Tegafur, a chemotherapy drug, and found no significant pharmacokinetic interaction.
This is a meaningful body of evidence. The consistency across 77 human clinical trials, including survival and quality-of-life outcomes, goes well beyond theoretical reassurance.
The critical context: the patients in these studies needed their immune function restored. The chemotherapy was the suppressive agent; the mushrooms counteracted it. This is the opposite of what happens in organ transplantation, where the suppression is the goal.
Why Transplant Patients Face a Different Risk Entirely
The concern for transplant patients taking mushroom supplements and immunosuppressants together can be stated directly: immune-modulating beta-glucans from turkey tail, reishi, and chaga stimulate natural killer cells and T-lymphocytes, which anti-rejection drugs are specifically designed to suppress. Lam et al.'s 77 clinical trials showed this combination was safe with chemotherapy, but those patients needed immune stimulation.[1] Transplant patients do not. No clinical studies have examined this combination.
The theoretical concern is acute rejection. In solid organ transplantation (kidney, liver, heart, lung), the immune system continuously samples donor tissue. Immunosuppressive drugs prevent the T-lymphocyte response that would otherwise destroy the organ. The drugs must maintain this suppression consistently, for years or decades, with narrow tolerances.
Whether the level of immune activation achievable from supplement doses of beta-glucans is sufficient to overcome the pharmacological suppression produced by therapeutic concentrations of cyclosporine or tacrolimus is genuinely unknown. Individual transplant patients vary considerably in their immune sensitivity, drug regimen, transplanted organ type, and time since transplant. No data exists to model this interaction quantitatively for any mushroom species or dose.
"No reported cases of rejection linked to mushroom supplements" is true. But it reflects the absence of formal research, not established safety. The absence of documented harm and evidence of no harm are different categories. For cancer patients on chemotherapy, we have evidence of no harm across 77 clinical trials. For transplant patients, neither category applies. There is simply no data.
The Cyclosporine Problem: Reishi May Raise Drug Levels Via a Liver Enzyme
Beyond immune stimulation, reishi raises a separate pharmacokinetic concern for transplant patients, one that operates through a completely different mechanism.
Cyclosporine and tacrolimus are both metabolized primarily by CYP3A4, an enzyme in the liver that breaks down a large fraction of commonly prescribed drugs. When CYP3A4 is inhibited, meaning slowed down, drugs that depend on it for clearance accumulate in the blood. Both cyclosporine and tacrolimus have narrow therapeutic windows: the blood level difference between effective immunosuppression and drug toxicity is small. Elevated cyclosporine causes kidney damage and high blood pressure. Elevated tacrolimus causes similar toxicity, including neurological effects.
A 2024 study by Li and colleagues, published in Frontiers in Pharmacology, evaluated 66 individual triterpenoid compounds isolated from Ganoderma lucidum (reishi) against seven CYP liver enzymes, including CYP3A4.[2] One compound, designated compound 25, inhibited CYP3A4 with measured IC50 values of 4.78 to 25.28 micromolar depending on the drug being tested. IC50 is the concentration that reduces enzyme activity by 50%. Li et al. also conducted an in vivo rat experiment, not just a test tube study, and confirmed that reishi triterpenoids at relevant concentrations altered how other drugs were processed by the liver in a living system.
The important limitation: clinical relevance at typical human supplement doses is unknown. Biochemical IC50 values reflect isolated enzyme systems. The concentrations of reishi triterpenoids that actually reach the liver after a person takes a standard supplement dose may be substantially lower than what was tested in vitro. Li et al. note this explicitly.[2]
What the data establishes: the mechanism exists and has been confirmed in a living animal system. Reishi contains compounds that demonstrably slow the enzyme responsible for clearing cyclosporine and tacrolimus. Whether this translates to clinically meaningful drug level changes at supplement doses in humans is uncharacterized. Given that cyclosporine toxicity has real and immediate clinical consequences for transplant patients, this mechanism is worth understanding clearly.
For a deeper look at how mushroom compounds affect CYP enzyme activity across multiple drug classes, see Mushrooms and Cytochrome P450: Do They Affect Drug Metabolism?.
Mushroom Safety and Immunosuppressants: Which Species Raise the Most Concern
Not every mushroom species poses the same level of concern for people on immunosuppressive therapy. Risk varies by the strength of each species' immunomodulatory evidence and whether it has additional pharmacokinetic effects.
Turkey tail (Trametes versicolor) carries the highest immunomodulatory evidence of any medicinal mushroom. PSK and PSP are specifically characterized as T-lymphocyte and natural killer cell activators, confirmed across 77 clinical trials.[1] For transplant patients, turkey tail is the highest-concern species on immune-stimulation grounds alone.
Reishi (Ganoderma lucidum) raises dual concerns: beta-glucan immune stimulation plus the CYP3A4 inhibition documented by Li et al. in 2024.[2] Transplant patients on cyclosporine or tacrolimus face both a theoretical immune activation concern and a plausible mechanism for pharmacokinetic drug level changes. Of the commonly available medicinal mushrooms, reishi has the most documented interaction pathways with transplant immunosuppressants.
Chaga (Inonotus obliquus) is among the most beta-glucan-dense medicinal mushrooms and activates innate immunity. Its immunomodulatory concern for transplant patients is real, though the clinical evidence base supporting the magnitude of its specific immune effects is thinner than for turkey tail.
Cordyceps has some documented immunomodulatory activity, but most research on cordyceps focuses on energy metabolism and oxygen utilization rather than lymphocyte activation directly. Its immune-stimulating concern is lower relative to turkey tail or reishi based on available evidence. For a full look at what cordyceps safety data shows, see Cordyceps Side Effects: What the Safety Research Shows.
Lion's mane (Hericium erinaceus) is studied primarily for neurological effects through nerve growth factor stimulation. Its immune-activating properties are much less prominent in the research literature compared to turkey tail, reishi, or chaga. Among commonly used medicinal mushrooms, lion's mane likely poses the lowest immunomodulatory concern for transplant patients, though no specific transplant safety data exists for it either.
Maitake (Grifola frondosa) has documented glucose-lowering and cardiovascular effects alongside some immune activity. For transplant patients who also manage diabetes, the interaction with glucose-lowering medications may be an additional concern, covered in Mushrooms and Diabetes Medications: Hypoglycemia Risk.
The Bottom Line
The evidence on mushrooms and immunosuppressants divides cleanly by patient population. For cancer patients receiving chemotherapy, Lam et al.'s 2020 systematic review of 77 clinical trials found no adverse interactions and generally improved immune outcomes. For organ transplant recipients, no clinical data exists. The pharmacological concern is mechanistically grounded: beta-glucans activate the T-lymphocytes that cyclosporine and tacrolimus specifically suppress, and reishi triterpenoids inhibit the liver enzyme that metabolizes both drugs. Whether these mechanisms produce clinically meaningful problems at supplement doses in humans is unknown. The gap between "safe for chemo patients" and "safe for transplant patients" is not semantic; it reflects a fundamental difference in why each population takes immunosuppressants and what the research has and has not tested.
Frequently Asked Questions
Sources & References
- 1RTHM-01225·Lam, Chun Sing et al. (2020). “Herb-drug interactions between the medicinal mushrooms Lingzhi and Yunzhi and cytotoxic anticancer drugs: a systematic review..” Chinese medicine.Study breakdown →PubMed →↩
- 2RTHM-01926·Li, Dawei et al. (2024). “Triterpenoids from Ganoderma lucidum inhibit cytochrome P450 enzymes interfering with the metabolic process of specific clinical drugs..” Frontiers in pharmacology.Study breakdown →PubMed →↩